KPD Consolidation After ASCT in NDMM Patients

This study tests a combination therapy called KPD (carfilzomib, pomalidomide, and dexamethasone) as consolidation treatment for newly diagnosed multiple myeloma patients who have recently completed a stem cell transplant. Consolidation means giving extra treatment after transplant to deepen the response and keep the cancer away longer. **You may be eligible if:** - You are 18 or older with newly diagnosed multiple myeloma - You were eligible for and received a stem cell transplant (ASCT) - You received a standard induction regimen of 3 or 4 drugs before your transplant - Your ECOG score is less than 2 (meaning you are able to care for yourself) - Your heart, liver, and kidney function are adequate **You may NOT be eligible if:** - Your myeloma was previously treated (not newly diagnosed) - You did not receive a stem cell transplant - Your organ function is significantly impaired - You have a serious active infection or another cancer Talk to your doctor to see if this trial is right for you.